These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35140513)

  • 21. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
    Lichtman AH; Lux EA; McQuade R; Rossetti S; Sanchez R; Sun W; Wright S; Kornyeyeva E; Fallon MT
    J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
    Mallada Frechín J
    Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
    BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of nabiximols oromucosal spray: a review of more than 15 years" accumulated evidence from clinical trials.
    Prieto González JM; Vila Silván C
    Expert Rev Neurother; 2021 Jul; 21(7):755-778. PubMed ID: 34092180
    [No Abstract]   [Full Text] [Related]  

  • 26. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
    Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
    J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P; Henze T; Zettl UK
    Eur Neurol; 2014; 72(1-2):95-102. PubMed ID: 24943098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.
    Zettl UK; Rommer P; Hipp P; Patejdl R
    Ther Adv Neurol Disord; 2016 Jan; 9(1):9-30. PubMed ID: 26788128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study.
    Chisari CG; Solaro C; Annunziata P; Bergamaschi R; Bianco A; Bonavita S; Brescia Morra V; Bruno Bossio R; Capello E; Castelli L; Cavalla P; Costantino G; Centonze D; Cottone S; Danni MC; Esposito F; Gajofatto A; Gasperini C; Guareschi A; Lanzillo R; Lus G; Maniscalco GT; Matta M; Paolicelli D; Petrucci L; Pontecorvo S; Righini I; Rovaris M; Sessa E; Spinicci G; Spitaleri D; Valentino P; Zaffaroni M; Zappia M; Patti F
    J Neurol Neurosurg Psychiatry; 2020 Sep; 91(9):914-920. PubMed ID: 32661083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health Authorities Data Collection of THC:CBD Oromucosal Spray (L'Agenzia Italiana del Farmaco Web Registry): Figures after 1.5 Years.
    Patti F
    Eur Neurol; 2016; 75 Suppl 1():9-12. PubMed ID: 26901344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
    Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
    PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M; Vila C
    Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. THC:CBD in Daily Practice: Available Data from UK, Germany and Spain.
    Fernández Ó
    Eur Neurol; 2016; 75 Suppl 1():1-3. PubMed ID: 26901342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
    Keating GM
    Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    Stott CG; White L; Wright S; Wilbraham D; Guy GW
    Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
    Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
    Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy, tolerability and safety of cannabis-based medicines for cancer pain : A systematic review with meta-analysis of randomised controlled trials.
    Häuser W; Welsch P; Klose P; Radbruch L; Fitzcharles MA
    Schmerz; 2019 Oct; 33(5):424-436. PubMed ID: 31073761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.